Prof. Ahmed Mudawi Musa CV

Personal details

Name   : Ahmed Mudawi Musa Mohammed

Date of birth : 01 January 1967

Place of birth : The central state, Sudan

Nationality : Sudanese

Marital status : Married

Language : Arabic (mother tongue), English (Fluent)

Present position : Associate Professor in Immunology, Institute of Endemic Diseases, University of Khartoum, Sudan

Address : Department of Clinical Pathology and Immunology, Institute of Endemic Diseases, University of Khartoum, Sudan,POBox 102,
www.iend.org,

Telephone : +249183793267 (work) +249 9180 43 288 (private)

Fax : +249183 779712
E-mail : This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.

Qualifications : MBBS (University of Khartoum, Sudan) Ph D immunology (University of Khartoum, Sudan) DTM&H (RCP, UK), MSc TM & IH (University of London, UK)

Registration : Permanently registered as a Qualified Medical officer 1997, SMC number 8828, (Sudan).

 

 

 

 

 

Educational qualifications

Undergraduate Medical education: MBBS, 24 October 1987 – 10 January 1994, Faculty of Medicine, University of Khartoum Sudan.

Postgraduate study, training and qualifications:

a) Ph D in Immunology, February 2001 – February 2006. Institute of Endemic Diseases, University of Khartoum, Sudan. Supervisors: Prof. Ahmed Mohammed EL- Hassan and Prof. Eltahir Awad Gasim Khalil. Registered as a specialist in Immunology in March 2006.
b) World Health Organization Training Programme in Clinical Trials Monitoring, From November 1998 to August 2003. Supervisor: Prof. Juntra Karbwang, WHO Clinical Trials Co-ordinator.
c) Training Course on Good Clinical Practice (GCP), Organised by WHO/TDR, NMIMR and UNAIDS Accra, Ghana, 09-17.11.1998.
d) Training Course on the use of Advanced Epidemiological Methods in Research, Organised by WHO/TDR and Navrongo Health Research Centre, Ghana, 17-24.07.2000.
e) Refresher Course on Good Clinical Practice (GCP), for WHO/TDR Clinical Trials Monitors, Organised by WHO/TDR and Thammasat University (Thailand), Bankok, 26-28.07.2001.
f) International course on Research Ethics, Organised by WHO/TDR, Bergen University (Norway), Thammasat University and FERCAP, Bankok, 30.07-03.08.2001.
g) Immunohistochemistry course, Institute of Endemic Diseases, University of Khartoum, Sudan, 03-11.09.2001.
h) The Third African Malaria Vaccine Testing Network (AMVTN) workshop on the Immunology and molecular Biology of malaria vaccines, Maputo, Mozambique, 18-22.02.2002.
i) Refresher Course on Good Clinical Practice (GCP), for WHO/TDR Clinical Trials Monitors, Organised by WHO/TDR, Chiang Mai, Thailand, 22-24.07.2002.
j) An International Conference On Good Health Practices in Asia and Western Pacific, Organised by FERCAP, Chiang Mai, Thailand, 25-26.07.2002.
k) Advanced WHO/TDR course on Immunology, Vaccinology and Biotechnology applied to Infectious Diseases, WHO Immunology Research and Training Centre, University of Lausanne (Switzerland), 12.09-25.10.2002.
l) Refresher course on GCP for WHO/TDR clinical trials monitors, Nagazaki Tropical Medicine Institute, Fukouoka, Japan 28-30.07.2003.
m) Refresher course on GCP for WHO/TDR Clinical Trials Monitors, Hua Hin, Thailand, 18-20.08.2004.
n) GCP training course for the investigators of DNDi (Drugs for neglected diseases initiatives) in preparation for a multicenter randomised controlled clinical trial to test Paromomycin versus SSG versus a combination of SSG and Paromomycin for treatment of visceral leishmaniasis, Khartoum, Sudan 26-27.09.2004.
o) Audiometry training course for the investigators of DNDi (Drugs for neglected diseases initiatives) in preparation for a multicenter randomised clinical trial to test Paromomycin versus SSG versus a combination of SSG and Paromomycin for treatment of visceral leishmaniasis, Khartoum, Sudan, November 2004.
p) Training course on design and conduct of clinical trials in Africa, organized by the Wellcome trust, University of cape Town, South Africa, 09-28.01.2006.
q) Refresher GCP course for WHO/TDR Clinical Trials monitors (16-18.8.2006) Thailand, Hua Hin.
r) Refresher training course on Audiometry for the investigators of DNDi (Drugs for neglected diseases initiatives) for A multicenter randomised clinical trial to test Paromomycin versus SSG versus a combination of SSG and Paromomycin for treatment of visceral leishmaniasis, Gedarif State, Kassab trial site, Sudan 02-03.11.2006.
s) Refresher GCP course for WHO/TDR Clinical Trials monitors (9-11.7.2006) Thailand, Hua Hin.
t) Pharmacovigilance Training course, on 11 September 2007, organized by the DSRU Education & Research Limited, at the Royal Society of Tropical Medicine, London, UK.
u) MSc in Tropical Medicine & International health 2009, University of London, United Kingdom.
v) Diploma Tropical Medicine & Hygiene, 2009, Royal College of Physician in London, United Kingdom.
w) Attended a training workshop on Intellectual property, New Delhi, India, 4.12.2010.

 

 

 

Academic appointments

i) Teaching Assistant: Department of Clinical pathology and Immunology, Institute of Endemic Diseases, University of Khartoum, Sudan, July 2000 to June 2005.
Department of Clinical pathology and Immunology, Institute of Endemic Diseases, University of Khartoum, Sudan, June 2005 to July 2006.
ii) Assistant Professor:
Department of Clinical pathology and Immunology, Institute of Endemic Diseases, University of Khartoum, Sudan, July 2006 to Feb 2010.
iii) Associate Professor:
Department of Clinical pathology and Immunology, Institute of Endemic Diseases, University of Khartoum, Sudan, Feb 2010 to date.

Occasions at which served as participant, adviser or consultant

1- World Health organisation:
WHO/TDR (15.01.1997 – 04.07.1999) On-site Clinical Trial Monitor and Member of Data & Safety Monitoring Board for a randomised, double-blind, BCG-controlled trial in Sudan (Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis): Lancet. 2000 Nov 4; 356 (9241):1565-9.
WHO/TDR Temporary advisor for a miltefosine as first line drug treatment for visceral leishmaniasis clinical trial, AHRI, Addis Ababa, Ethiopia (March-Nov. 2003).
WHO/TDR Product Development Team (PDT) Meeting on Future Plans for leishmaniasis vaccines development (consultant), department of Clinical Pathology and Immunology, Institute of Endemic Diseases, University of Khartoum, Sudan, 21-22.02.2003. WHO/TDR Temporary advisor for a clinical trial of Safety, tolerability and Pharmacokinetic studies on the combination therapy of Praziquantel + Oxamniquine (PZQ + OXA). Study on normal Volunteers, the Academy of Health Sciences and Technology, Khartoum, Sudan (Feb. 2006 ongoing). Invited as an expert for a consultative meeting on the development of therapeutic vaccines for post kala-azar dermal leishmaniasis (PKDL), W4115, WHO/TDR Casai, Geneva 8-9 December 2005 (Published in Kinetoplastid, Ghalib H and Modabber F, 2007), presented a talk about immunochemotherapy of PKDL studies in Sudan. Invited as an expert for a consultative meeting on the development of therapeutic vaccines for post kala-azar dermal leishmaniasis (PKDL), W4115, WHO/TDR Casai, Geneva 7- 8 August 2006. Developing a protocol for immunochemotherapy of PKDL using second generation vaccine (Leish 111f). Consultant, member of the World Health OrganizatiOrganization Expert committee on Leishmaniasis control, Geneva (2009-ongoing). 2. Sudan Facilitator, Seminar on Health Research Ethics, Organised by the Institute of Endemic Diseases, University of Khartoum, Presented a talk about the Concept of Good Clinical Practice (GCP), 23.08.2001.

Advisor, Workshop on Developing a National Policy on Leishmaniasis Control in the Sudan. (Federal Ministry of Health, Sudan; WHO; MSF-Holland) Khartoum, Sudan, 23rd – 24th February 2003.

Facilitator, ethics in clinical research, Federal Ministry of health, Faculty of medicine and the Institute of Endemic Diseases, University of Khartoum, Sudan, 22-26.06.06.

Organizer and Facilitator, ethics of health research training for community lay people, Kassab site, Gedarif State, Eastern Sudan, 4-6 June 2007. Facilitator, Best Practices in Ethical Review, a workshop for members of Ethics Committees in Sudan organized by Tropical Medicine Research Institute and HAT platform (DNDi), Khartoum, Sudan 24-26.7.2007. Speaker, HAT Platform annual meeting, 27-29.11.2007, presented a talk about LEAP experience, Grand Villa Holiday, Khartoum, Sudan. Facilitator, Winter course of Life Sciences on Immunology organized by the School of Life Sciences, faculty of Science and Technology, Alneelain University in collaboration with the International Union of Immunological societies & The Federation of African Immunological Societies, 5-10 January 2008.

3. Drugs for Neglected Diseases initiatives (DNDi) Consultant for DNDi (Drugs for neglected diseases initiatives) 2nd LEAP (Leishmaniasis East Africa Platform) meeting on Finding a new drug or combination of drugs for treatment of visceral leishmaniasis, Khartoum, Sudan 25-26.08.2003. Consultant for DNDi (Drugs for neglected diseases initiatives) the 3rd
Consultant, Regional DNDi (Drugs for neglected diseases initiatives) the 4th LEAP (Leishmaniasis East Africa Platform) meeting on preparation for A multicenter randomised clinical trial to test Paromomycin versus SSG versus a combination of SSG and Paromomycin for treatment of visceral leishmaniasis, KEMRI, Kenya, 8- LEAP (Leishmaniasis East Africa Platform) meeting on preparation for a multicenter randomised clinical trial to test Paromomycin versus SSG versus a combination of SSG and Paromomycin for treatment of visceral leishmaniasis, Addis Ababa, Ethipia 12-13.05.2004.
13
9.10.2004. Consultant for DNDi (Drugs for neglected diseases initiatives) 5th LEAP (Leishmaniasis East Africa Platform) meeting on the progress of A multicenter randomised clinical trial to test Paromomycin versus SSG versus a combination of SSG and Paromomycin for treatment of visceral leishmaniasis, Khartoum, Sudan 11-12.03.2005. Consultant, 1st DNDi (Drugs for neglected diseases initiatives) consultative meeting on intrim analysis of A multicenter randomised clinical trial to test Paromomycin versus SSG versus a combination of SSG and Paromomycin for treatment of visceral leishmaniasis, KEMRI, Kenya, 20-21.06.2005. Consultant, regional DNDi (Drugs for neglected diseases initiatives) 6th LEAP (Leishmaniasis East Africa Platform) meeting on the progress of A multicenter randomised clinical trial to test Paromomycin versus SSG versus a combination of SSG and Paromomycin for treatment of visceral leishmaniasis, Addis Ababa, Ethiopia 11-12.02.2006

Consultant, 2nd DNDi consultative meeting on the pharmacokinetics sub-study analysis as part of the multicenter randomised clinical trial to test Paromomycin versus SSG versus a combination of SSG and Paromomycin for treatment of visceral leishmaniasis,8-9.06.06, KEMRI, Nairobi, Kenya. Clinical Trial Monitoring expert, DNDi clinical Trials monitors meeting 5-6.02.2007, Nairobi, Kenya. Consultant, regional DNDi (Drugs for neglected diseases initiatives) 8th LEAP (Leishmaniasis East Africa Platform) meeting on the progress of A multicenter randomised clinical trial to test Paromomycin versus SSG versus a combination of SSG and Paromomycin for treatment of visceral leishmaniasis, Kampala, Uganda 15-16.03.2007.

Consultant, regional DNDi (Drugs for neglected diseases initiatives) 9th LEAP (Leishmaniasis East Africa Platform) meeting on the progress of A multicenter randomised clinical trial to test Paromomycin versus SSG versus a combination of SSG and Paromomycin for treatment of visceral leishmaniasis, London, United Kingdom, 09-10.09.2007. Consultant, regional DNDi (Drugs for neglected diseases initiatives) 10th LEAP (Leishmaniasis East Africa Platform) meeting on the progress of A multicenter randomised clinical trial to test Paromomycin versus SSG versus a combination of SSG and Paromomycin for treatment of visceral leishmaniasis, Khartoum, Sudan 19-20.02.2008

DNDi PIs meeting to discuss the ongoing research project (LEAP 0104B) and future research projects of combination therapies for treatment of visceral leishmaniaiasis, KEMRI, Nairobi, Kneya, 08-09.05.2008. Trainer for DNDi Clinical Trial site staff at Amudat Hospital, Uganda. Training for one week on Diagnosis and management of patients with visceral leishmaniasis. The training was composed of bedside and laboratory clinical teaching to prepare the site for joining the LEAP 0104B project, Amudat hospital, Uganda, 11-17.07.2008. Consultant, regional DNDi (Drugs for neglected diseases initiatives) 11th LEAP (Leishmaniasis East Africa Platform) meeting on the progress of A multicenter randomised clinical trial to test Paromomycin versus SSG versus a combination of SSG and Paromomycin for treatment of visceral leishmaniasis, Addis Ababa, Ethiopia, 28-29.08.2008

4. Others Participant, invited by the DNDi (Drugs for neglected diseases initiatives) the 11th
Participant, The centenary meeting of the Royal Society of Tropical Medicine 13- parasitology congress, Glasgow, United Kingdom, 6-11.08.06.
15
15.9.2007, London, UK.

Participant, Dormy II meeting 24-27.9.2007 functional genomic of leishmania vaccines, York University, UK. Speaker, 59th American Society of Tropical Medicine & Hygiene; Presented the results of the LEAP0104B clinical trial which concluded that a 17-day course of sodium stibogluconate in combination with paromomycin is a suitable first line treatment for treatment of visceral leishmaniasis in East Africa, 3-7.11.2010. Panelist, 3rd
1. Khalil EAG, Kamil AA, Mukhtar MM, Musa AM, Ibrahim ME, Modabber F, Sacks D, Smith PG, Zicker F and EL-Hassan AM. Intradermal injection of Alum-adsorbed ALM vaccine Plus BCG promotes induction of Th1 cytokines in healthy volunteers. Oral presentation; Oxford 2000, New Challenges in Tropical Medicine and Parasitology. stakeholders meeting of DNDi, improving access to treatment of visceral leishmaniasis in East Africa, New Delhi, 3.12.2010.

Memberships of Learned Societies (year of entry) Sudanese Leishmaniasis Research Group (1997, Institute of Endemic Diseases, U. of Khartoum). Tuberculosis Research Group (2000, Institute of Endemic Diseases, U. of Khartoum). Sudanese Clinical biology society (2003). Leishmaniasis East Africa Platform (LEAP) 2003. Sudanese Society of Immunologist (2008 to date)

Contributions to Scientific Conferences, Meetings, Symposia

1.Khalil EAG, Kamil AA, Mukhtar MM, Musa AM, Ibrahim ME, Modabber F, Sacks D, Smith PG, Zicker F and EL-Hassan AM. Intradermal injection of Alum-adsorbed ALM vaccine Plus BCG promotes induction of Th1 cytokines in healthy volunteers. Oral presentation; Oxford 2000, New Challenges in Tropical Medicine and Parasitology

2.Musa AM, Khalil EAG, Ismail A, Fesharki H, Khamesipour A, Modabber F, Elhassan IM and El-Hassan AM. Immunochemotherapy of patients with persistent post kala-azar dermal leishmaniasis (PKDL): a pilot study of safety and possible efficacy. Oral presentation and abstract. Conference on endemic and infectious diseases in Sudan, Ministry of Science and Technology, National Centre for Research, Tropical Medicine Research Institute, Institute of Endemic Diseases, WHO/TDR and Federal Ministry of Health, Sudan. Sharja Hall 5-8 May 2003.
3. Elamin WM, Guerbouj S, Guizani I, Bakhiet SM, El-Hassan SM, El_Hassan AM, Musa AM, Kheir MM and Mukhtar MM. Leishmania archibaldi is the major cause of leishmaniasis in the Sudan. Oral presentation and abstract. Conference on endemic and infectious diseases in Sudan, Ministry of Science and Technology, National Centre for Research,Tropical Medicine Research Institute, Institute of Endemic Diseases, WHO/TDR and Federal Ministry of Health, Sudan. Sharja Hall 5-8 May 2003.
4. Yousif NM, Jensen AT, Musa AM, El-Hassan AM, Khalil EAG and Elhassan IM. Anti-glucose regulated protein 78 (GRP78) antibody responses in Alum/ALM + BCG vaccinees, visceral leishmaniasis and post kala-azar dermal leishmaniasis patients. Oral presentation and abstract. Conference on endemic and infectious diseases in Sudan, Ministry of Science and Technology, National Centre for Research, Tropical Medicine Research Institute, Institute of Endemic Diseases, WHO/TDR and Federal Ministry of Health, Sudan. Sharja Hall 5-8 May 2003.
5. Ayed NB, Musa AM and Khalil EAG. Surrogate markers of immunity to human visceral leishmaniasis. Oral presentation and abstract. Conference on endemic and infectious diseases in Sudan, Ministry of Science and Technology, National Centre for Research, Tropical Medicine Research Institute, Institute of Endemic Diseases, WHO/TDR and Federal Ministry of Health, Sudan. Sharja Hall 5-8 May 2003.
6. Elyamani LE, Khalil EAG, Ibrahim ME, Musa AM and Elhassan IM. Malaria transmission in two villages characterized by seasonal but stable malaria transmission in eastern Sudan. Oral presentation and abstract. Conference on endemic and infectious diseases in Sudan, Ministry of Science and Technology, National Centre for Research, Tropical Medicine Research Institute, Institute of Endemic Diseases, WHO/TDR and Federal Ministry of Health, Sudan. Sharja Hall 5-8 May 2003.
7. Musa AM. Oral presentation. The challenges of managing kala-azar patients in Sudan. DNDi symposium, the 25th African Scientist congress, Nairobi Kenya, 4-8.10.2005.
8. Manal Fadl, E Nancy Miller, M Fakiola, Hiba SM, sara E, A Elzein, EAG Khalil, A M El-Hassan, A M Musa, M E Ibrahim, J M Blackwell. Genome Wide search for visceral leishmaniasis susceptibility genes in Sudanese Population. AMST 3 African Scientist congress, Nairobi, Kenya, 4-8.10.2005.
rd Annual scientific conference, Khartoum, 26th Nov – 3rd
9. Khalil EAG, El-Hassan AM, Musa AM, Zijlstra EE, Ibrahim ME, Mukhtar MM, Modabber F, Zicker F, Keiney MP and Smith PG. Vaccines for visceral leishmaniasis: Sudanese experience. Oral presentation and Abstract: Journal of Clinical Laboratory, XI Congress of the Arab Federation of Clinical Biology, 29th  April to 1 May 2006..
10.Khalil EAG, El-Hassan AM, Musa AM, Zijlstra EE, Ibrahim ME, Mukhtar MM, Modabber F, Zicker F, Keiney MP and Smith PG. Vaccines for visceral leishmaniasis: Sudanese experience. Oral presentation and Abstract: Sudanese Society of Clinical biology, the first Scientific Conference Khartoum, Sudan, Friendship Hall 24 April to 1 May 2006.
th – 27th
11.Khalil EAG, El-Hassan AM, Musa AM, Zijlstra EE, Ibrahim ME, Mukhtar MM, Modabber F, Zicker F, Keiney MP and Smith PG. Vaccines for visceral leishmaniasis: Sudanese experience. Oral presentation and Abstract: Sudanese Society of Clinical biology, the first Scientific Conference Khartoum, Sudan, Friendship Hall 24 November 2006.
th – 27th
12.Musa AM, Khalil EAG, Mahgoub FA, Hamad S, Modabber F, Elkadaru AMY, Aboud MH, Karbwang J, Noazin S and El- Hassan AM. Immunochemotherapy of persistent post kala-azar dermal leishmaniasis: a novel approach of treatment. Oral presentation and Abstract: Sudanese Society of Clinical biology, the first Scientific Conference Khartoum, Sudan, Friendship Hall 24 November 2006.
th – 27th
13. Ismail WMA, Khalil EAG, Bygbjerg IC, Osman, FM, Musa AM and El-Hassan. Coverage & efficacy of BCG vaccination in displaced populations: a measure of effectiveness of expanded program of immunization. Poster and Abstract. Sudanese Society of Clinical biology, the first Scientific Conference Khartoum, November 2006.
18
Sudan, Friendship Hall 24th – 27th
14. Bernawi AAA, Khalil EAG, Morsi AN, Abdelgalil K, Yassin HM and Musa AM. Sero-prevalence and exposure rates of human Echinoccus granulosus infection in Southern Libya. Poster and Abstract. Sudanese Society of Clinical biology, the first Scientific Conference Khartoum, Sudan, Friendship Hall 24 November 2006.
th – 27th
15.Elagib AH, Ahmed AE, Hussein A, Musa AM, Khalil EAG and El-Hassan. Possible predisposing factors for thrombotic cerebrovascular accidents (CVAs) in Sudanese patients. Poster and Abstract. Sudanese Society of Clinical biology, the first Scientific Conference Khartoum, Sudan, Friendship Hall 24th – 27thNovember 2006.
16.Elnour AA, Khalil EAG, Hamad S and Musa AM. Tuberculous Lymphadenitis: Skin delayed type hypersensitivity reaction and cytokines profile as markers of disease and healing. Poster and Abstract. Sudanese Society of Clinical biology, the first Scientific Conference Khartoum, Sudan, Friendship Hall 24 November 2006.
th – 27th
17. El-Hassan OM, Khalil EAG and Musa AM. Trachoma in a cluster of villages of internally displaced population (IDP) in eastern Sudan: Comparison between clinical & serological diagnoses. Poster and Abstract. Sudanese Society of Clinical biology, the first Scientific Conference Khartoum, Sudan, Friendship Hall 24November 2006.
th – 27th
18.Khidir SAE, Khalil EAG, Musa AM and El-hassan AM. Th1/Th2 to Th1 immune response switch: the case of post kala-azar dermal leishmaniasis. Poster and Abstract. Sudanese Society of Clinical biology, the first Scientific Conference Khartoum, Sudan, Friendship Hall 24 November 2006.
th – 27th
19.Hamad S, Khalil EAG, Musa AM, Ibrahim ME and El-Hassan AM. In vitro induction of resistance to sodium stibogluconate (SSG) in Leishmania donovani donovani isolates from Sudan. Poster and Abstract. Sudanese Society of Clinical biology, the first Scientific Conference Khartoum, Sudan, Friendship Hall 24 November 2006.
th – 27th
20. Salih MA, Ibrahim ME, Blackwell JM, Miller EN, Khalil EAG, El-Hassan AM, Musa AM and Mohammed HS. IFNG and IFNGR1 gene polymorphisms and November 2006.
19
susceptibility to post kala-azar dermal leishmaniasis in Sudan. Poster and Abstract. Sudanese Society of Clinical biology, the first Scientific Conference Khartoum, Sudan, Friendship Hall 24th – 27th
21. Musa AM, oral presentation about the preliminary results and further dose ranging of paromomycin for visceral leishmaniasis- Kassab, Sudan, DNDi symposium UK; A step together in the Right direction: LEAP investigates paromomycin to treat visceral leishmaniasis in Africa, Queen Elizabeth II Conference Centre, London, UK, 13.9.2007. November 2006.

 

 

 

Contributions to Scientific Conferences, Meetings, Symposia

1.Khalil EAG, Kamil AA, Mukhtar MM, Musa AM, Ibrahim ME, Modabber F, Sacks D, Smith PG, Zicker F and EL-Hassan AM. Intradermal injection of Alum-adsorbed ALM vaccine Plus BCG promotes induction of Th1 cytokines in healthy volunteers. Oral presentation; Oxford 2000, New Challenges in Tropical Medicine and Parasitology

2.Musa AM, Khalil EAG, Ismail A, Fesharki H, Khamesipour A, Modabber F, Elhassan IM and El-Hassan AM. Immunochemotherapy of patients with persistent post kala-azar dermal leishmaniasis (PKDL): a pilot study of safety and possible efficacy. Oral presentation and abstract. Conference on endemic and infectious diseases in Sudan, Ministry of Science and Technology, National Centre for Research, Tropical Medicine Research Institute, Institute of Endemic Diseases, WHO/TDR and Federal Ministry of Health, Sudan. Sharja Hall 5-8 May 2003.
3. Elamin WM, Guerbouj S, Guizani I, Bakhiet SM, El-Hassan SM, El_Hassan AM, Musa AM, Kheir MM and Mukhtar MM. Leishmania archibaldi is the major cause of leishmaniasis in the Sudan. Oral presentation and abstract. Conference on endemic and infectious diseases in Sudan, Ministry of Science and Technology, National Centre for Research,Tropical Medicine Research Institute, Institute of Endemic Diseases, WHO/TDR and Federal Ministry of Health, Sudan. Sharja Hall 5-8 May 2003.
4. Yousif NM, Jensen AT, Musa AM, El-Hassan AM, Khalil EAG and Elhassan IM. Anti-glucose regulated protein 78 (GRP78) antibody responses in Alum/ALM + BCG vaccinees, visceral leishmaniasis and post kala-azar dermal leishmaniasis patients. Oral presentation and abstract. Conference on endemic and infectious diseases in Sudan, Ministry of Science and Technology, National Centre for Research, Tropical Medicine Research Institute, Institute of Endemic Diseases, WHO/TDR and Federal Ministry of Health, Sudan. Sharja Hall 5-8 May 2003.
5. Ayed NB, Musa AM and Khalil EAG. Surrogate markers of immunity to human visceral leishmaniasis. Oral presentation and abstract. Conference on endemic and infectious diseases in Sudan, Ministry of Science and Technology, National Centre for Research, Tropical Medicine Research Institute, Institute of Endemic Diseases, WHO/TDR and Federal Ministry of Health, Sudan. Sharja Hall 5-8 May 2003.
6. Elyamani LE, Khalil EAG, Ibrahim ME, Musa AM and Elhassan IM. Malaria transmission in two villages characterized by seasonal but stable malaria transmission in eastern Sudan. Oral presentation and abstract. Conference on endemic and infectious diseases in Sudan, Ministry of Science and Technology, National Centre for Research, Tropical Medicine Research Institute, Institute of Endemic Diseases, WHO/TDR and Federal Ministry of Health, Sudan. Sharja Hall 5-8 May 2003.
7. Musa AM. Oral presentation. The challenges of managing kala-azar patients in Sudan. DNDi symposium, the 25th African Scientist congress, Nairobi Kenya, 4-8.10.2005.
8. Manal Fadl, E Nancy Miller, M Fakiola, Hiba SM, sara E, A Elzein, EAG Khalil, A M El-Hassan, A M Musa, M E Ibrahim, J M Blackwell. Genome Wide search for visceral leishmaniasis susceptibility genes in Sudanese Population. AMST 3 African Scientist congress, Nairobi, Kenya, 4-8.10.2005.
rd Annual scientific conference, Khartoum, 26th Nov – 3rd
9. Khalil EAG, El-Hassan AM, Musa AM, Zijlstra EE, Ibrahim ME, Mukhtar MM, Modabber F, Zicker F, Keiney MP and Smith PG. Vaccines for visceral leishmaniasis: Sudanese experience. Oral presentation and Abstract: Journal of Clinical Laboratory, XI Congress of the Arab Federation of Clinical Biology, 29th  April to 1 May 2006..
10.Khalil EAG, El-Hassan AM, Musa AM, Zijlstra EE, Ibrahim ME, Mukhtar MM, Modabber F, Zicker F, Keiney MP and Smith PG. Vaccines for visceral leishmaniasis: Sudanese experience. Oral presentation and Abstract: Sudanese Society of Clinical biology, the first Scientific Conference Khartoum, Sudan, Friendship Hall 24 April to 1 May 2006.
th – 27th
11.Khalil EAG, El-Hassan AM, Musa AM, Zijlstra EE, Ibrahim ME, Mukhtar MM, Modabber F, Zicker F, Keiney MP and Smith PG. Vaccines for visceral leishmaniasis: Sudanese experience. Oral presentation and Abstract: Sudanese Society of Clinical biology, the first Scientific Conference Khartoum, Sudan, Friendship Hall 24 November 2006.
th – 27th
12.Musa AM, Khalil EAG, Mahgoub FA, Hamad S, Modabber F, Elkadaru AMY, Aboud MH, Karbwang J, Noazin S and El- Hassan AM. Immunochemotherapy of persistent post kala-azar dermal leishmaniasis: a novel approach of treatment. Oral presentation and Abstract: Sudanese Society of Clinical biology, the first Scientific Conference Khartoum, Sudan, Friendship Hall 24 November 2006.
th – 27th
13. Ismail WMA, Khalil EAG, Bygbjerg IC, Osman, FM, Musa AM and El-Hassan. Coverage & efficacy of BCG vaccination in displaced populations: a measure of effectiveness of expanded program of immunization. Poster and Abstract. Sudanese Society of Clinical biology, the first Scientific Conference Khartoum, November 2006.
18
Sudan, Friendship Hall 24th – 27th
14. Bernawi AAA, Khalil EAG, Morsi AN, Abdelgalil K, Yassin HM and Musa AM. Sero-prevalence and exposure rates of human Echinoccus granulosus infection in Southern Libya. Poster and Abstract. Sudanese Society of Clinical biology, the first Scientific Conference Khartoum, Sudan, Friendship Hall 24 November 2006.
th – 27th
15.Elagib AH, Ahmed AE, Hussein A, Musa AM, Khalil EAG and El-Hassan. Possible predisposing factors for thrombotic cerebrovascular accidents (CVAs) in Sudanese patients. Poster and Abstract. Sudanese Society of Clinical biology, the first Scientific Conference Khartoum, Sudan, Friendship Hall 24th – 27thNovember 2006.
16.Elnour AA, Khalil EAG, Hamad S and Musa AM. Tuberculous Lymphadenitis: Skin delayed type hypersensitivity reaction and cytokines profile as markers of disease and healing. Poster and Abstract. Sudanese Society of Clinical biology, the first Scientific Conference Khartoum, Sudan, Friendship Hall 24 November 2006.
th – 27th
17. El-Hassan OM, Khalil EAG and Musa AM. Trachoma in a cluster of villages of internally displaced population (IDP) in eastern Sudan: Comparison between clinical & serological diagnoses. Poster and Abstract. Sudanese Society of Clinical biology, the first Scientific Conference Khartoum, Sudan, Friendship Hall 24November 2006.
th – 27th
18.Khidir SAE, Khalil EAG, Musa AM and El-hassan AM. Th1/Th2 to Th1 immune response switch: the case of post kala-azar dermal leishmaniasis. Poster and Abstract. Sudanese Society of Clinical biology, the first Scientific Conference Khartoum, Sudan, Friendship Hall 24 November 2006.
th – 27th
19.Hamad S, Khalil EAG, Musa AM, Ibrahim ME and El-Hassan AM. In vitro induction of resistance to sodium stibogluconate (SSG) in Leishmania donovani donovani isolates from Sudan. Poster and Abstract. Sudanese Society of Clinical biology, the first Scientific Conference Khartoum, Sudan, Friendship Hall 24 November 2006.
th – 27th
20. Salih MA, Ibrahim ME, Blackwell JM, Miller EN, Khalil EAG, El-Hassan AM, Musa AM and Mohammed HS. IFNG and IFNGR1 gene polymorphisms and November 2006.
19
susceptibility to post kala-azar dermal leishmaniasis in Sudan. Poster and Abstract. Sudanese Society of Clinical biology, the first Scientific Conference Khartoum, Sudan, Friendship Hall 24th – 27th
21. Musa AM, oral presentation about the preliminary results and further dose ranging of paromomycin for visceral leishmaniasis- Kassab, Sudan, DNDi symposium UK; A step together in the Right direction: LEAP investigates paromomycin to treat visceral leishmaniasis in Africa, Queen Elizabeth II Conference Centre, London, UK, 13.9.2007. November 2006.

Publications

Books
1. Priorities of Health Research Setting in Kassala state (2000), Directorate of Research, Federal Ministry of Health, Sudan.
2. Sudanese Post Kala-azar Dermal Leishmaniasis: Natural history, Immunology and Immunochemotherapy. PhD degree awarded, February 2006. (Ph D thesis, University of Khartoum).
3. AM EL-Hassan, Lamyaa AM EL-Hassan and AM Musa. Complement and Glomerulonephritis 2012, in Nur EL Huda’s textbook of glomerulonephritis, fourth edition, M Nur EL Huda Ed, pp 37-49.

4.Musa, Ahmed M.; Elhassan, Ahmed M.; Mukhtar, Moawia M.; etal. , Alum-precipitated Autoclaved Leishmania Major plus Bacille Calmette-Guérrin,A candidate Vaccine for Visceral Leishmaniasis: Safety, Skin-Delayed type Hypersensitivity Response and Dose Finding in Healthy Volunteers.

5.Musa, Ahmed M.; Elhassan, Ahmed M.; Khalil, Eltahir Awad G,etal, Anti – Glucose Regulated Protein 78 (GRP78) antibody responses in Alum/ALM plus BCG vaccinee, visceral leishmaniasis, and Post Kala- azar Dermal leishmaniasis patients .

6. Khalil, Eltahir Awad G.; Musa, Ahmed M.; Elhassan, Ahmed M.; ., etal ,Anti-Leishmania Donovani Antibodies Enhance Promastigotes Internalization into Host Macrophage.

7. Khalil, Eltahir Awad G; Musa, Ahmed M.; Elhassan, Ahmed M; ., etal ,Blindness Following Visceral Leishmaniasis : A Neglected Post-Kala-Azar Complication.

8. Khalil, Eltahir Awad G.; Elhassan, Ahmed M.; Musa, Ahmed M.; Mukhtar, Moawia M.; etal,Dichotomy Of Protective Cellular Immune Responses To Human Visceral Leishmaniasis.

12. Musa, Ahmed M.; Khalil, Eltahir Awad G.; Mahgoub, Fawzi Abd Elrahim; Hassab, Sara Hamad; Elkadarud, Abd Elgadir Mohamed Yousif

9. Musa, Ahmed M.; Nimir, Ahmed A; Khalil, Eltahir Awad G , Evaluation of the particle gel diffusion technique for the detection of haemoglobin S in Sudanese patients. Ann Clin Biochem; 46:114-6. Epub

10. Musa, Ahmed M.; Khalil, Eltahir Awad G.; etal. Efficacy of Liposomal Amphotericin B (Ambisome®) In the Treatment of Persistent Post-Kala-Azar Dermal Leishmaniasis (PKDL)

11. Fakiola, Michaela; Miller, E. Nancy; Fadl, Manal; Musa, Ahmed M,Genetic and Functional Evidence Implicating DLL1 as the Gene That Influences Susceptibility to Visceral Leishmaniasis at Chromosome 6q27

12.Musa, Ahmed M.; Khalil, Eltahir Awad G.; Mahgoub, Fawzi Abd Elrahim; Immunochemotherapy of persistent postkala- azar dermal leishmaniasis: a novel approach to treatmen.

13. Baraka, Omer Z.; Mukhtar, Moawia M.; Musa, Ahmed M.; etal.Immunocompetence may be Important in The Effectiveness of Mectizan® (ivermectin) in the Treatment of Human.

14. Khalil, Eltahir Awad G.; Musa, Ahmed M.; Elhassan, Ahmed M.; ., etal .Immunogenicity and Immune Modulatory Effects of in Silico Predicted L. Donovani Candidate Peptide Vaccines.

15. Alkadarou, Tayseer; Musa, Ahmed M.; Alkadarou, Abedelgader; S.Mahfouz, Mohamed ,Immunological Characteristics of Hyperreactive Malarial Splenomegaly Syndrome in Sudanese Patients.

16. Musa, Ahmed M.; Noazin, Sassan; Khalil, Eltahir Awad G ,Immunological stimulation for the treatment of leishmaniasis: A modality worthy of serious consideration.

17.Musa, Ahmed M.; Khalil, Eltahir Awad G , Immunological stimulation for the treatment of leishmaniasis: a modality worthy of serious consideration.Trans R Soc Trop Med Hyg. 104(1):1-2.  

18.Salih, Mohamed A M; Fakiola, Michaela; Abdelraheem, Mohamed H; Musa, Ahmed M. , Insights into the possible role of IFNG and IFNGR1 in Kala-azar and Post Kala-azar Dermal Leishmaniasis in Sudanese patients .

19. Khalil, Eltahir Awad G.; Ibrahim, Muntaser E.; Salih, Mohamed; Musa, Ahmed M. ,Interleukin 10 Gene Polymorphisms and Development of Post Kala-Azar Dermal Leishmaniasis in a Selected Sudanese Population.

20. Musa, Ahmed M.; Khalil, Eltahir Awad G; Hamad, S.H. ,Leishmania Donovani: Genetic Diversity Of Isolates From Sudan Characterized By PCR-Based RAPD.

21. Musa, Ahmed M.; Elhassan, Ahmed M; Khalil, Eltahir Awad G; ., etal, Leishmania: Probable Genetic Hybrids between Species in Sudanese Isolates.

22. Wani, Charles E.; Ibrahim, Muntaser E.; Musa, Ahmed M. ,Molecular Characterization of Sudanese and Southern Sudanese Chicken Breeds Using mtDNA D-Loop.

23. Musa, Ahmed M.; Khalil, Eltahir Awad G.; reeham, M. A. ,The natural history of Sudanese post-kala-azar dermal leishmaniasis: clinical, immunological and prognostic features.

24. Musa, Ahmed M.; Khalil, Eltahir Awad G; ., etal ,The pathogenesis of post kala-azar dermal leishmaniasis from the field to the molecule: Does ultraviolet light (UVB) radiation play a role?

25. Elhassan, Ahmed M.; Musa, Ahmed M.; Khalil, Eltahir Awad G.; etal. ,Post-kala-azar Dermal Leishmaniasis.

26.  Musa, Ahmed M.; Musa, Brima; Khalil, Eltahir Awad G.; Khidir, Selma Abdelmoneim , Post-Kala-Azar Dermal Leishmaniasis: A Paradigm of Paradoxical Immune Reconstitution Syndrome in Non-HIV/AIDS Patients.

27. Khalil, Eltahir Awad G; Musa, Ahmed M.; Salih, Kawthar Abd Eljalil Mohamed ,Prevalence of latent tuberculosis infection in Sudan: A case-control study comparing interferon-γ release assay and tuberculin skin test.

28. Khalil, Eltahir Awad G; Musa, Ahmed M. ,Safety & Immunogenicity of a Candidate Vaccine for Visceral Leishmaniasis (Alum-Precipitated Autoclaved L.Major +BCG) In Children: An Extended Phase II Study. Annals of Tropical Paediatrics.

29. Khalil, Eltahir Awad G; Edwards, Tansy; Musa, Ahmed M.; ., etal ,Single-Dose Liposomal Amphotericin B (Ambisome®) for the Treatment of Visceral Leishmaniasis in East Africa: Study Protocol for a Randomized Controlled Trial.

30. Musa, Ahmed M.; Khalil, Eltahir Awad G.; Hailu, Asrat ,Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial.

31. Abdel Hamid, Muzamil M.; M. Elamin, Elwaleed; E. Melville, Sara; Musa, Ahmed M.; M. Blackwell, Jenefer ,Sudanese mucosal leishmaniasis: isolation of a parasite within the Leishmania donovani complex that differs genotypically from L. donovani causing classical visceral leishmaniasis.

33.   Musa, Ahmed M.; Khalil, Eltahir Awad G.; Younis, B.M; etal ,Treatment-Based Strategy for the Management of Post-Kala-Azar Dermal Leishmaniasis Patients in the Sudan .

34 . Hailu, Asrat; Musa, Ahmed M. ,Visceral Leishmaniasis: New Health Tools Are Needed.

 

 

Follow Us